Google News
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline NovartisNovartis makes $3B oncology play AxiosNovartis to Buy Breas...
Source: Google News
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline NovartisNovartis makes $3B oncology play AxiosNovartis to Buy Breast Cancer Drug for as Much as $3 Billion Bloomberg.comNovartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Business WireNovartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug TipRanks